Dianthus Therapeutics, Inc. (DNTH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.9M	2.0M	6.2M	2.8M	6.4M
Cost of Revenue	76.0K	—	—	—	—
Gross Profit	1.8M	2.0M	6.2M	2.8M	6.4M
Operating Expenses
R&D Expense	175.6M	145.6M	83.1M	32.8M	29.4M
SG&A Expense	44.1M	34.3M	25.0M	18.2M	6.7M
General & Admin Expense	44.1M	34.3M	25.0M	18.2M	6.7M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	219.7M	180.0M	108.1M	51.0M	36.1M
Cost and Expenses	219.7M	180.0M	108.1M	51.0M	36.1M
Operating Income (EBIT)	(217.8M)	(177.9M)	(101.9M)	(48.2M)	(29.7M)
Non-Operating
Interest Income	26.7M	16.1M	17.4M	4.8M	1.1M
Interest Expense	—	—	—	—	—
Net Interest Income	26.7M	16.1M	17.4M	4.8M	1.1M
Other Non-Op Income/Expense	187.9M	15.6M	16.9M	4.6M	1.2M
Non-Operating Income (excl Interest)	(187.9M)	(15.6M)	(16.9M)	(4.6M)	(1.2M)
EBT (Pre-Tax Income)	(29.9M)	(162.3M)	(85.0M)	(43.6M)	(28.5M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(29.9M)	(162.3M)	(85.0M)	(43.6M)	(28.5M)
Earnings from Cont. Ops	(29.9M)	(162.3M)	(85.0M)	(43.6M)	(28.5M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(29.9M)	(162.3M)	(85.0M)	(43.6M)	(28.5M)
Per Share
Basic EPS	($0.13)	($4.20)	($2.55)	($8.45)	($7.60)
Diluted EPS	($0.13)	($4.20)	($2.55)	($8.45)	($7.60)
Revenue Per Share	$0.03	$0.05	$0.19	$0.55	$1.71
Shares
Basic Shares Outstanding	56.0M	37.8M	33.3M	5.2M	3.7M
Diluted Shares Outstanding	56.0M	37.8M	33.3M	5.2M	3.7M
Profitability Metrics
EBITDA	(29.5M)	(161.9M)	(84.6M)	(43.2M)	(28.3M)
D&A	399.0K	428.0K	412.0K	355.0K	147.0K
EBIT	(29.9M)	(162.3M)	(85.0M)	(43.6M)	(28.5M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026